Presenters
Course Details
HPN in CKD: Achieving Control Amidst the Pandemic? Part I
Patients with diabetes mellitus are prone to developing kidney disease, especially in the presence of hypertension. In this video, Dr. Romeo Santos (Philippine Heart Center) shared the various clinical studies demonstrating the renal benefits of telmisartan in patients with diabetes mellitus.
Estimated time of Completion: 7 mins. 51 secs.
HPN in CKD: Achieving Control Amidst the Pandemic? Part II
Clinicians face many challenges in ensuring blood pressure control in their patients in real-world clinical practice. In this short video, Dr. Romeo Santos (Philippine Heart Center) and Dr. Froilan de Leon provide practical tips to optimize patient outcomes when treating hypertension and address concerns associated with antihypertensive treatment.
Estimated time of Completion: 4 mins. 2 secs.
CPD Points: 0.75 Points
HPN in CKD: Achieving Control Amidst the Pandemic? Course Outline
- 2020 ISH Simplified Classification of Hypertension Risk
- Initiation of anti-hypertension treatment
- High-risk Patients: Advantage of RAAS inhibitors
- Unique “delta lock” structure of Telmisartan
- Pharmacological Profile of Telmisartan
- The Trough/Peak Ratio
- Comparative Pharmacokinetic Profile
- Telmisartan’s Long Duration of Effect
- ONTARGET: Telmisartan as Effective as Ramipril in Preventing CV Events at Increased CV Risk
- Telmisartan versus Ramipril in renal ENdothelial DYsfunction study
- Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study
- telMisartan (80 mg) vs. losArtan (100 mg) in hypertensive type-2 DiabEtic patients with Overt nephropathy
- Telmisartan is efficient along the renal continuum
PC-PH-104611 / February 2023